Pure Global AI
NCT05595642Recruiting

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
Hoffmann-La RochePhase 2/3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease (COPD)
Drug/Device/Intervention
Astegolimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hoffmann-La Roche
Location
Miami,Edmond, United States of America
Timeline & enrollment
Phase
Phase 2/3
Start date
Dec 29, 2022
End date
Jun 01, 2025
Enrollment
1290 participants
Primary outcome

Annualized rate of moderate and severe COPD exacerbations over the 52-week treatment period

Summary

This study will evaluate the efficacy and safety of astegolimab compared with placebo in
 participants with chronic obstructive pulmonary disease (COPD) who are former or current
 smokers and have a history of frequent exacerbations.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05595642
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05595642 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 1290 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.